News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
309,375 Results
Type
Article (15692)
Company Profile (302)
Press Release (293375)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (85674)
Career Advice (235)
Deals (14216)
Drug Delivery (40)
Drug Development (54027)
Employer Resources (31)
FDA (6819)
Job Trends (5786)
News (156338)
Policy (11255)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (995)
Accelerated approval (24)
Adcomms (14)
Allergies (90)
Alliances (22924)
ALS (135)
Alzheimer's disease (1194)
Antibody-drug conjugate (ADC) (280)
Approvals (7115)
Artificial intelligence (347)
Autoimmune disease (128)
Automation (24)
Bankruptcy (108)
Best Places to Work (5276)
BIOSECURE Act (6)
Biosimilars (118)
Biotechnology (231)
Bladder cancer (141)
Brain cancer (49)
Breast cancer (504)
Cancer (3912)
Cardiovascular disease (290)
Career advice (208)
Career pathing (7)
CAR-T (229)
CDC (6)
Cell therapy (615)
Cervical cancer (21)
Clinical research (47225)
Collaboration (1368)
Company closure (2)
Compensation (812)
Complete response letters (41)
COVID-19 (1212)
CRISPR (89)
C-suite (634)
Cystic fibrosis (124)
Data (5154)
Denatured (15)
Depression (100)
Diabetes (291)
Diagnostics (1917)
Digital health (20)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (210)
Drug pricing (59)
Drug shortages (4)
Duchenne muscular dystrophy (220)
Earnings (36571)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (55820)
Executive appointments (758)
FDA (9068)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (1177)
Gene editing (189)
Generative AI (26)
Gene therapy (532)
GLP-1 (560)
Government (1353)
Grass and pollen (5)
Guidances (247)
Healthcare (7243)
HIV (37)
Huntington's disease (43)
IgA nephropathy (83)
Immunology and inflammation (205)
Immuno-oncology (41)
Indications (77)
Infectious disease (1355)
Inflammatory bowel disease (164)
Inflation Reduction Act (11)
Influenza (55)
Intellectual property (184)
Interviews (29)
IPO (8003)
IRA (13)
Job creations (904)
Job search strategy (185)
JPM (41)
Kidney cancer (11)
Labor market (22)
Layoffs (248)
Leadership (9)
Legal (1562)
Liver cancer (53)
Longevity (13)
Lung cancer (545)
Lymphoma (306)
Machine learning (27)
Management (7)
Manufacturing (462)
MASH (138)
Medical device (3389)
Medtech (3406)
Mergers & acquisitions (7022)
Metabolic disorders (802)
Multiple sclerosis (120)
NASH (13)
Neurodegenerative disease (262)
Neuropsychiatric disorders (74)
Neuroscience (2211)
Neurotech (1)
NextGen: Class of 2026 (2189)
Non-profit (1028)
Now hiring (32)
Obesity (357)
Opinion (131)
Ovarian cancer (149)
Pain (125)
Pancreatic cancer (185)
Parkinson's disease (257)
Partnered (13)
Patents (343)
Patient recruitment (385)
Peanut (44)
People (27816)
Pharmaceutical (44)
Pharmacy benefit managers (10)
Phase 1 (16252)
Phase 2 (21435)
Phase 3 (14506)
Pipeline (3962)
Policy (93)
Postmarket research (1077)
Preclinical (6780)
Press Release (31)
Prostate cancer (188)
Psychedelics (50)
Radiopharmaceuticals (244)
Rare diseases (713)
Real estate (1544)
Recruiting (12)
Regulatory (11263)
Reports (20)
Research institute (1062)
Resumes & cover letters (31)
Rett syndrome (26)
RNA editing (21)
RSV (33)
Schizophrenia (131)
Series A (201)
Series B (160)
Service/supplier (2)
Sickle cell disease (88)
Special edition (18)
Spinal muscular atrophy (120)
Sponsored (18)
Startups (2053)
State (1)
Stomach cancer (7)
Supply chain (53)
Tariffs (19)
The Weekly (62)
Vaccines (428)
Venture capital (71)
Weight loss (183)
Women's health (39)
Worklife (2)
Date
Last 7 days (430)
Last 30 days (1504)
Last 365 days (22404)
2026 (2049)
2025 (22845)
2024 (23219)
2023 (23965)
2022 (28885)
2021 (29684)
2020 (25359)
2019 (17776)
2018 (13062)
2017 (14941)
2016 (12864)
2015 (15488)
2014 (11123)
2013 (7977)
2012 (8064)
2011 (8229)
2010 (8002)
Location
Africa (187)
Alabama (70)
Alaska (2)
Arizona (88)
Arkansas (8)
Asia (19704)
Australia (3301)
California (8730)
Canada (2164)
China (864)
Colorado (284)
Connecticut (360)
Delaware (309)
Europe (43529)
Florida (1049)
Georgia (254)
Hawaii (3)
Idaho (19)
Illinois (572)
India (43)
Indiana (210)
Iowa (13)
Japan (352)
Kansas (83)
Kentucky (12)
Louisiana (10)
Maine (13)
Maryland (890)
Massachusetts (6659)
Michigan (159)
Minnesota (312)
Mississippi (3)
Missouri (63)
Montana (16)
Nebraska (7)
Nevada (76)
New Hampshire (33)
New Jersey (2268)
New Mexico (14)
New York (2246)
North Carolina (950)
North Dakota (7)
Northern California (4285)
Ohio (231)
Oklahoma (12)
Oregon (27)
Pennsylvania (1499)
Puerto Rico (10)
Rhode Island (27)
South America (268)
South Carolina (10)
Southern California (3397)
Tennessee (76)
Texas (1208)
United States (29002)
Utah (123)
Virginia (194)
Washington D.C. (45)
Washington State (679)
West Virginia (2)
Wisconsin (102)
309,375 Results for "g1 therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Remedy Plan Therapeutics Advances RPT1G for Myeloid Cancer Patients with Phase 1 Safety Data and IND Approval
November 13, 2025
·
4 min read
Press Releases
Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
December 4, 2025
·
5 min read
Press Releases
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N
January 7, 2026
·
7 min read
Press Releases
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors
October 27, 2025
·
6 min read
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
G1 Therapeutics, Inc. announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets, Monday, July 1, 2024.
July 1, 2024
·
3 min read
Press Releases
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
December 30, 2025
·
10 min read
Deals
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 5, 2024
G1 Therapeutics, Inc. today announced the grant of inducement stock options exercisable for 4,650 shares of G1’s common stock and 2,400 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).
June 5, 2024
·
2 min read
Press Releases
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
October 19, 2025
·
9 min read
Business
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the first quarter ended March 31, 2024.
May 1, 2024
·
10 min read
Bio NC
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 01, 2024
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
May 1, 2024
·
2 min read
1 of 30,938
Next
